Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Journal of Clinical Pharmacy and Pharmaceutical Science
Wilis Rakhmadhanti
Politeknik Katolik Mangunwijaya Semarang
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
EVALUASI BIAYA KEMOTERAPI PASIEN EARLY BREAST CANCER DI RSUD TUGUREJO SEMARANG PERIODE JULI-DESEMBER 2018 Wilis Rakhmadhanti; Fef Rukminingsih
Journal Clinical Pharmacy and Pharmaceutical Science Vol. 1 No. 1 (2022): April: Journal of Clinical Pharmacy and Pharmaceutical Science
Publisher : Prodi D3 Farmasi Politeknik Katolik Mangunwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61740/jcp2s.v1i1.1

Abstract

Early breast cancer (EBC) is defined as with or without in a breast cancer, but it has not metastasized to wider tissue. Chemotherapy expense  has 59% portion of the total cost of cander patients at the hospital. There were 137 EBC patients visit during January-March 2018 conducted at Tugurejo Regional Hospital Semarang. Therefore, research is needed to evaluate the cost of chemotherapy in EBC patient in Tugurejo  Hospital Semarang. This study was an observational descriptive study with a cross sectional study design. Data sources were gained from Medical Record (MR) data and billing / billing data for National Health Insurance (JKN) participant patients with an EBC diagnosis undergoing chemotherapy at Tugurejo Hospital Semarang in the period July-December 2018. The inclusion criteria for this study was JKN patients with EBC diagnosis age 17 -65 years who did chemotherapy at Tugurejo General Hospital Semarang in the period July-December 2018. Data was processed qualitatively and quantitatively. The results of evaluation of  the cost of chemotherapy for EBC patients at Tugurejo Hospital Semarang in the period July-December 2018 were done with the regimen Doxorubicin-Doxetacel-Fluorouracil (AT-F) Rp 3.683.388,00 ± 193.960, Doxetacel-Epirubicin-Fluorouracil (TE-F) Rp 4.342.914 00 ± 37.614, Fluorouracil-Epirubicin-Cyclofosphamid (FEC) Rp 2.929.464,00 ± 193.960, Fluorouracil-Doxorubicin-Cyclofosphamid (FAC) amounting to Rp2.471.671,00 ± 193.960.  
Co-Authors Fef Rukminingsih